Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.

Authors

• Jaume Capdevila
• Ignacio Matos
• Francesco M Mancuso
• Carmela Iglesias
• Paolo Nuciforo
• Carles Zafon
• Hector G Palmer
• Zighereda Ogbah
• Laura Muiños
• Jorge Hernando
• Guillermo Villacampa
• Carol E Peña
• Josep Tabernero
• Marcia S Brose
• Martin Schlumberger
• Ana Vivancos

Publication/Presentation Date

1-1-2020

Abstract

Several biomarkers have been suggested to have prognostic value in differentiated thyroid carcinomas (DTC) with no validation in the refractory setting, including all tumor subtypes. We aim to correlate RNA expression profiles with survival based on patients included in the DECISION trial. We obtained 247 samples from the 417 patients included in the DECISION study and performed RNAseq analysis (77 million paired-end reads for each sample on HiSeq2000). After quality control, 125 samples were included in the secondary analysis and mapped against the human reference genome (GRCh38) with STAR (v2.5.1b) using ENCODE parameter. Survival analysis was calculated using the Kaplan-Meier method and log-rank test was used for statistical comparison. In this

Volume

19

Issue

1

First Page

312

Last Page

317

ISSN

1538-8514

Published In/Presented At

Capdevila, J., Matos, I., Mancuso, F. M., Iglesias, C., Nuciforo, P., Zafon, C., Palmer, H. G., Ogbah, Z., Muiños, L., Hernando, J., Villacampa, G., Peña, C. E., Tabernero, J., Brose, M. S., Schlumberger, M., & Vivancos, A. (2020). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular cancer therapeutics, 19(1), 312–317. https://doi.org/10.1158/1535-7163.MCT-19-0211

Disciplines

Medicine and Health Sciences

PubMedID

31540966

Department(s)

Hematology-Medical Oncology Division

Document Type

Article